STOCK TITAN

InspireMD director Gary S. Roubin buys 153,846 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

InspireMD, Inc. director Gary S. Roubin purchased 153,846 common shares and 115,385 Series L common stock warrants in the company’s underwritten public offering on November 13, 2026, at a combined public offering price of $0.65 per common share and accompanying warrants. His reported holdings afterward were 988,324 common shares and 115,385 warrants. No Rule 10b5-1 plan is reported.

Insider ROUBIN GARY S
Role Director
Bought 269,231 shs ($100K)
Type Security Shares Price Value
Purchase Series L Common Stock Warrant F2 115,385 $0.00 $0.00
Purchase Common Stock F1 153,846 $0.65 $100K
Holdings After Transaction: Series L Common Stock Warrant — 115,385 warrants (Direct); Common Stock — 988,324 shares (Direct)
Footnotes (2)
  1. F1. Represents shares of common stock purchased by the Reporting Person in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
  2. F2. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
Common shares purchased 153,846 shares Gary S. Roubin’s purchase on November 13, 2026
Series L warrants purchased 115,385 warrants Gary S. Roubin’s purchase on November 13, 2026
Combined public offering price $0.65 per common share and accompanying warrants Underwritten public offering
Warrant exercise price $0.65 per share Series L common stock warrants
Common shares held after transaction 988,324 shares Gary S. Roubin’s reported position
Warrants held after transaction 115,385 warrants Gary S. Roubin’s reported position
underwritten public offering financial
"purchased in the Issuer's underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
Series L common stock warrants technical
"accompanying Series L common stock warrants"
exercise price financial
"immediately exercisable at an exercise price of $0.65 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NSPR shares did Gary S. Roubin buy, and at what price?

Gary S. Roubin purchased 153,846 common shares on November 13, 2026, in InspireMD’s underwritten public offering. The combined public offering price was $0.65 per common share and accompanying warrants.

What are the terms of Gary S. Roubin’s NSPR Series L warrants?

The 115,385 Series L common stock warrants are immediately exercisable at $0.65 per share and expire November 16, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ROUBIN GARY S

(Last)(First)(Middle)
C/O INSPIREMD, INC.
6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)
MIAMI FLORIDA 33126

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/13/2026P153,846(1)A$0.65988,324D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series L Common Stock Warrant(2)$0.6511/13/2026P115,38511/16/202611/16/2027Common Stock115,385$0.00115,385D
Explanation of Responses:
1. Represents shares of common stock purchased by the Reporting Person in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
2. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
/s/ Michael Lawless, Attorney-in-Fact for Gary S. Roubin11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading